Print

DBV Technologies and INRA Receive Funding to Develop Pediatric Bronchiolitis ("RSV") Vaccine: RSV-NanoViaSkin  
1/15/2013 9:37:31 AM

BAGNEUX, France--(BUSINESS WIRE)--Regulatory News: DBV Technologies (Euronext: DBV – ISIN: FR0010417345) (Paris:DBV), creator of Viaskin®, a new standard in the treatment of allergies, announced today that the Company and the French Institute for Agricultural Research-INRA (Molecular Virology and Immunology Unit, VIM-U892) have been awarded a research grant of nearly €600.000 from the French National Research Agency (ANR) to develop an innovative, efficient and safe pediatric ‘RSV’ bronchiolitis (‘RSV’) vaccine. RSV-NanoViaSkin is intended to become the world’s first non-invasive and adjuvant-free epicutaneous RSV pediatric vaccine.
//-->